| Original language | English |
|---|---|
| Pages (from-to) | 366-368 |
| Number of pages | 3 |
| Journal | International journal of hematology |
| Volume | 109 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2019 Mar 20 |
ASJC Scopus subject areas
- Hematology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies : final analysis of phase I study. / Tobinai, Kensei; Uchida, Toshiki; Fukuhara, Noriko et al.
In: International journal of hematology, Vol. 109, No. 3, 20.03.2019, p. 366-368.Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Ibrutinib in Japanese patients with relapsed/refractory B-cell malignancies
T2 - final analysis of phase I study
AU - Tobinai, Kensei
AU - Uchida, Toshiki
AU - Fukuhara, Noriko
AU - Nishikawa, Tomoaki
N1 - Funding Information: This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Acknowledgements This study was funded by Janssen Pharmaceutical K.K. We thank the patients who participated in this trial and their families. Writing assistance was provided by Safeer Mughal, PhD, of PAREXEL, and was funded by Janssen Global Services. The data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. Funding Information: Conflict of interest KT received grants and personal fees from Cel-gene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Mundipharma, Ono, Takeda; personal fees from HUYA and Zenyaku Kogyo; grants from AbbVie, GSK SERVIER. NF received grants from Janssen. TU received personal fees from BMS, Celgene, Chugai, Eisai, Janssen, Kyowa Hakko Kirin, Novartis, Mundipharma, Nippon Shinyaku, Ot-suka, Pfizer Takeda. TN is employed by Janssen.
PY - 2019/3/20
Y1 - 2019/3/20
UR - http://www.scopus.com/inward/record.url?scp=85059685366&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85059685366&partnerID=8YFLogxK
U2 - 10.1007/s12185-018-02577-8
DO - 10.1007/s12185-018-02577-8
M3 - Letter
C2 - 30623356
AN - SCOPUS:85059685366
VL - 109
SP - 366
EP - 368
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 3
ER -